How big is the Middle East And Africa Glucagon-like Peptide-1 Agonists Market?

The Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 133.35 million in 2025 and grow at a CAGR of 7.26% to reach USD 189.31 million by 2030. Read More

What is the current Middle East And Africa Glucagon-like Peptide-1 Agonists Market size?

In 2025, the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 133.35 million. Read More

Who are the key players in Middle East And Africa Glucagon-like Peptide-1 Agonists Market?

AstraZeneca, Sanofi, Eli Lilly and Company, Novo Nordisk A/S and Pfizer Inc. are the major companies operating in the Middle East And Africa Glucagon-like Peptide-1 Agonists Market. Read More

What years does this Middle East And Africa Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2024?

In 2024, the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size was estimated at USD 123.67 million. The report covers the Middle East And Africa Glucagon-like Peptide-1 Agonists Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030. Read More

Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Companies

This report lists the top Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists industry.